Search results

Narrow your search

Result types
Article type
Jurisdiction
Practice area
Industry sector

Showing 1861 - 1870 of 2135 for "Copyright %26 related rights" with applied filters

News & Analysis

Beginning of TRABİS Era: Recent Shift in Application Regarding “.tr” Domain Names

23 July 2023 by Simaj Patent & Trademark Attorneys

“.tr” domain names had been managed by a platform, “nic.tr”, in Middle East Technical University since 1991 in Turkey. Well, no more. A long-awaited change has finally entered into force in Turkey. In fact, back in 2010, a platform called “.tr Network Information System” (“TRABIS”) was introduced by Information and Technologies Authority (“ICTA”), via the Internet Domain Names Regulation (“Regulation”). Enforcement of the Regulation was postponed until TRABIS starts operation. Finally, on 14 September 2022, TRABIS became operational, and this recent change is of grave importance.

News & Analysis

NFTs and their scope of ownership in current IP legislation

14 July 2023 by Simaj Patent & Trademark Attorneys

For centuries, civilization emerged rather gradually despite humankind’s passion and ambition, making it readily possible to regulate almost any development on a legal infrastructure that is unbiased and commonly held. In the recent past on the other hand, during modernization with the industrial revolutions, it was now a chase, but people were out front, taming the technological progress even though the advancements thrived in the midst of the inevitably evolving technology.

News & Analysis

Press release: Basham Ringe y Correa appoints four new partners

03 July 2023 by Basham Ringe y Correa

Basham Ringe y Correa announced the appointment of four new partners, strengthening its professional structure in the market and refreshing the leadership of its practice groups. These appointments reflect the Mexican firm's commitment to excellence, professionalism, and client satisfaction.

News & Analysis

The uncertainty about uncertainty – the new ground of sufficiency in Singapore

13 June 2023 by Drew & Napier

Tony Yeo, Meryl Koh and Javier Yeo of Drew & Napier analyse the Singapore Court of Appeal’s decision in IIa Technologies Pte Ltd v Element Six Technologies Limited [2023] SGCA 5 (“IIa v E6”)

News & Analysis

A trend in appeals the Indian Registrar of Trademarks

09 May 2023 by LexOrbis

Manisha Singh and Ritika Agarwal of LexOrbis analyse recent rulings by the High Court of Delhi in appeals against decisions by the Registrar of Trademarks

News & Analysis

Women Founders interview: Ana-Maria Baciu

28 April 2023 by Ana-Maria Baciu

Ana-Maria Baciu talks about setting up her own firm, Simion & Baciu, and recent client matters

News & Analysis

Women Founders interview: Alexandra Dellmeier

25 April 2023 by Alexandra Dellmeier

Alexandra Dellmeier of LexDellmeier Intellectual Property Office talks about her career in IP and running her own firm

News & Analysis

Why Brazil is important to a patent portfolio strategy

21 April 2023 by Otto Licks and Rodrigo Maior (Licks Attorneys)

Otto Licks and Rodrigo Maior of Licks Attorneys explains why Brazil is important to patent portfolio strategy

News & Analysis

Skinny label in Brazil: Drug authority seeking to implement new regulations

29 March 2023 by Roberto Rodrigues Pinho and Ricardo Campello (Licks Attorneys)

Roberto Rodrigues Pinho and Ricardo Campello of Licks Attorneys analyses Brazil's legislation and regulation concerning skinny labelling

News & Analysis

Patenting antibody-related inventions in Brazil

11 January 2023 by Rob Rodrigues, Danielle Altomari, Priscila Figueiredo, Ivan Domith

The healthcare sector in Brazil is one of the most important in the world in view of the size of the population (+220 million people) and the availability of a universal public healthcare system. The action of antibodies as therapeutic agents may involve processes of neutralization, opsonization and activation of immune complement system, transforming them into a progressively desirable tool in medicine. In view of this, the interaction between IP and these innovative therapies deserves special attention.